145 related articles for article (PubMed ID: 16801915)
21. Expression of CX3CL1 (fractalkine) in mice with endothelial-target rickettsial infection of the spotted-fever group.
Valbuena G; Walker DH
Virchows Arch; 2005 Jan; 446(1):21-7. PubMed ID: 15480764
[TBL] [Abstract][Full Text] [Related]
22. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis.
Cybulsky MI; Hegele RA
J Clin Invest; 2003 Apr; 111(8):1118-20. PubMed ID: 12697729
[No Abstract] [Full Text] [Related]
23. Polymorphisms in the 3' untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression.
Peraire J; Vidal F; Plana M; Domingo P; Coll B; Viladés C; Garcia F; Veloso S; Gatell JM; Broch M
AIDS; 2007 Apr; 21(7):891-3. PubMed ID: 17415055
[No Abstract] [Full Text] [Related]
24. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
25. Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?
Lauro C; Catalano M; Trettel F; Limatola C
Ann N Y Acad Sci; 2015 Sep; 1351():141-8. PubMed ID: 26084002
[TBL] [Abstract][Full Text] [Related]
26. The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement.
Morabito F; Merendino RA; Penna G; Cuzzola M; Stelitano C; Callea V; Di Pasquale G; Minciullo PL; Gangemi S
Acta Haematol; 2005; 113(2):152-4. PubMed ID: 15802897
[No Abstract] [Full Text] [Related]
27. Fractalkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices.
Bertollini C; Ragozzino D; Gross C; Limatola C; Eusebi F
Neuropharmacology; 2006 Sep; 51(4):816-21. PubMed ID: 16815480
[TBL] [Abstract][Full Text] [Related]
28. Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn.
Owolabi SA; Saab CY
FEBS Lett; 2006 Aug; 580(18):4306-10. PubMed ID: 16842787
[TBL] [Abstract][Full Text] [Related]
29. C and CX3C chemokines: cell sources and physiopathological implications.
Stievano L; Piovan E; Amadori A
Crit Rev Immunol; 2004; 24(3):205-28. PubMed ID: 15482255
[TBL] [Abstract][Full Text] [Related]
30. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells.
Durkan AM; Alexander RT; Liu GY; Rui M; Femia G; Robinson LA
J Am Soc Nephrol; 2007 Jan; 18(1):74-83. PubMed ID: 17151328
[TBL] [Abstract][Full Text] [Related]
31. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attentuates microglial activation in vivo and in vitro.
Lyons A; Lynch AM; Downer EJ; Hanley R; O'Sullivan JB; Smith A; Lynch MA
J Neurochem; 2009 Sep; 110(5):1547-56. PubMed ID: 19627440
[TBL] [Abstract][Full Text] [Related]
32. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma.
Matsubara T; Ono T; Yamanoi A; Tachibana M; Nagasue N
J Surg Oncol; 2007 Mar; 95(3):241-9. PubMed ID: 17323338
[TBL] [Abstract][Full Text] [Related]
33. Chemokines: what chemokine is that?
Mackay CR
Curr Biol; 1997 Jun; 7(6):R384-6. PubMed ID: 9197234
[TBL] [Abstract][Full Text] [Related]
34. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.
Diguet E; Gross CE; Tison F; Bezard E
Exp Neurol; 2004 Sep; 189(1):1-4. PubMed ID: 15296829
[TBL] [Abstract][Full Text] [Related]
35. The CX3CL1-CX3CR1 system and psoriasis.
Plant D; Young HS; Watson RE; Worthington J; Griffiths CE
Exp Dermatol; 2006 Nov; 15(11):900-3. PubMed ID: 17002687
[TBL] [Abstract][Full Text] [Related]
36. Fractalkine targeting with a receptor-mimicking peptide-amphiphile.
Kokkoli E; Kasinskas RW; Mardilovich A; Garg A
Biomacromolecules; 2005; 6(3):1272-9. PubMed ID: 15877342
[TBL] [Abstract][Full Text] [Related]
37. Microglia in Health and Disease.
Ransohoff RM; El Khoury J
Cold Spring Harb Perspect Biol; 2015 Sep; 8(1):a020560. PubMed ID: 26354893
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of in vivo neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons.
Shevtsova Z; Malik I; Garrido M; Schöll U; Bähr M; Kügler S
Gene Ther; 2006 Nov; 13(22):1569-78. PubMed ID: 16838029
[TBL] [Abstract][Full Text] [Related]
39. The brain as a target for inflammatory processes and neuroprotective strategies.
Skaper SD
Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
[TBL] [Abstract][Full Text] [Related]
40. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.
You JJ; Yang CH; Huang JS; Chen MS; Yang CM
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5290-8. PubMed ID: 17962485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
